PANK-003
/ Celconta Group
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 30, 2025
PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC
(clinicaltrials.gov)
- P2 | N=142 | Not yet recruiting | Sponsor: Shenzhen Celconta Life Science Co., Ltd.
New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
March 26, 2025
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Shenzhen Celconta Life Science Co., Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1